Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/03/202403150-zhong.jpg)
跨境医疗创新:新加坡患者在中国迎战骨髓瘤——一次CAR-T治疗的决定性旅程
跨境医疗创新:新加坡患者在中国迎战骨髓瘤——一次CAR-T治疗的决定性旅程
![多发性骨髓瘤,患者故事](https://www.medtourcn.com/wp-content/uploads/2024/03/202403150-zhong.jpg)
多发性骨髓瘤,患者故事
新加坡患者Teresa女士,经历了近三年与多发性骨髓瘤的斗争,她目前在多线药物治疗、放化疗后仍面临病情复发,髓外浆细胞瘤同时伴有脑、肝、多处骨病变。近期,她在接受上海嘉会国际医院的Dr. Vicky Lee及其团队线上会诊后,做出了一个重要决定:到中国接受FUCASO CAR-T治疗。
中国不仅在CAR-T治疗领域具有全球领先的临床经验,还有处于全球价格洼地的优质商业化CAR-T产品。目前这些已在中国上市的CAR-T产品产能充足,这对于与死神竞速的患者来说至关重要。同时因其仅一针输注的便捷性,已经备受国际患者的关注。
在上海嘉会国际医院,经验丰富的血液肿瘤专家团队将为Teresa制定个性化的治疗方案,并提供全程、精细化的诊疗服务。作为CAR-T治疗的先行者,嘉会医院即将为Teresa女士带来新生的希望。
我们将持续关注患者的治疗后续,并跟进报道。
#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #与癌症抗争 #CART治疗之旅 #携手嘉会 #全人源CAR-T #健康重生 #共同祈愿 #骨髓瘤 #多发性骨髓瘤 #Multiplemyeloma #患者故事 #HopeForPatients
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401221.png)
Breakthrough in Reducing Lupus with Successful Application of CAR-T Dual Target Technology
🌈Breakthrough in Reducing Lupus with Successful Application of CAR-T Dual Target Technology 🌟
![Lupus](https://www.medtourcn.com/wp-content/uploads/2024/01/202401221.png)
Lupus
![Lupus](https://www.medtourcn.com/wp-content/uploads/2024/01/202401222.png)
Lupus
🙌 Yin expressed her gratitude, saying: “The red spots on my body have disappeared, and I no longer need hormone medications or immunosuppressants. My mental state is also great, and all indicators are excellent. Today is my third checkup, and the results of the first two were also very positive. I thank these healthcare professionals for giving me a second life.”
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401160.jpg)
🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰
🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰
🌞In summary, CAR-T therapy presents a promising avenue for patients facing challenging lymphoma scenarios. The successful case of Mr. Li underscores the potential efficacy and safety of this innovative treatment at Peking Union Medical College Hospital.
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/01055.png)
Two Years of Complete Remission(Lymphoma), CAR-T therapy has given her a new lease on life.
“Two Years of Complete Remission, CAR-T therapy has given her a new lease on life. She Thought the Journey Was Over”
Yun is a 78-year-old patient who achieved a continuous complete remission for two and a half years despite relapsed/refractory diffuse large B-cell lymphoma. Diagnosed in 2019, after enduring six rounds of chemotherapy, she initially achieved complete remission as confirmed by her healthcare team. Unfortunately, the period of remission was short-lived as Yun soon experienced disease relapse, and subsequent second-line treatments failed to yield positive results.
“I vividly remember when Director Wang Li encouraged me, mentioning an advanced method called Car-T, but it was quite expensive. I was hesitant, but I discussed it with my son when I got home. When my son and daughter-in-law heard about it, they insisted on treatment. My son said, ‘Mom, you’re the only mother I have in this world. As long as you’re here, our home is complete. Money can be earned again, and if the treatment isn’t successful, at least we won’t have regrets.’ I was deeply moved. At my age, I’ve already shown strength through previous treatments. I believe that wherever my health takes me is where I belong. Everyone’s support gave me a reason to stay strong again.”
In 2021, CAR-T cell therapy was approved and launched in China, and Yun underwent this treatment at Ruijin Hospital.
Dr. Wang Li, Director of Hematology at Ruijin Hospital, explained, “CAR-T cell therapy provides new treatment options for a wide range of cancer patients.”
“Before planning Yun’s CAR-T cell therapy, lymphoma experts, considering her current tumor status and medical history, anticipated potential adverse reactions during the treatment process and discussed handling protocols. Yun’s entire journey with CAR-T cell therapy was challenging. The medical team meticulously coordinated their efforts, successfully addressing adverse reactions after CAR-T treatment, ultimately averting potential risks.”
Despite lying in her hospital bed, Yun deeply appreciates the relentless dedication of her medical caregivers. “Sometimes, directors come to see me after 10 p.m., telling me they worked late but had to check on me; some arrive by my bedside as early as 7 a.m., concerned about my well-being. I continuously remind myself that I must strive, persist, and live up to the efforts made by doctors and my entire family,” said the 78-year-old Yun . “I made it through.”
#CARTCellSuccess #CancerWarrior #CompleteRemissionChronicles #FamilySupportMatters #CAR-TBreakthrough #InspiringHealthJourney #MedicalMiracles #NeverTooLateToFight #Cancerfight #Bloodcancer
#lymphoma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2023/12/12282.jpeg)
Breakthrough in CAR-T Therapy Achieved by Chinese Sun Yat-sen University Cancer Center
Recently, Professor Huang Huiqiang’s team at Sun Yat-sen University Affiliated Cancer Hospital achieved significant progress in a lymphoma patient who relapsed after five lines of chemotherapy. Utilizing CAR-T therapy, the patient has experienced complete remission for over two years, making them one of the patients in China with the longest survival post-CAR-T treatment.
Lymphoma, one of the common blood cancers, has traditionally been treated using a combination of chemotherapy, autologous hematopoietic stem cell transplantation, targeted therapies, and immune-modulating drugs. However, CAR-T cell therapy, an advanced technology in the field of oncology, has emerged as a precise, rapid, and highly effective new treatment method in recent years.
Diffuse large B-cell lymphoma is a prevalent aggressive lymphoma characterized by rapid progression, high mortality rates, and short survival periods. Despite significant therapeutic advancements in recent years, approximately 70% of patients achieve good outcomes and long-term remission through first-line treatments, but around 30% of patients have inadequate responses to treatment, facing difficult-to-cure relapses.
Professor Huang Huiqiang emphasized, “CAR-T cell therapy plays a crucial role in providing new treatment hopes for relapsed and refractory patients who cannot undergo transplantation or have previously undergone ineffective treatments.
It is reported that in the future, Sun Yat-sen University Cancer Center will continue to explore clinical innovative technologies in CAR-T cell therapy, aiming to bring new prospects for numerous patients.
#CARTBreakthrough #CancerResearch #SunYatSenCancerCenter #InnovativeTherapies #MedicalBreakthrough #LymphomaTreatment #PrecisionMedicine #HopeForPatients #CancerSurvivorship #AdvancedOncology #MedicalInnovation #ResearchProgress #ScienceNews #HealthcareAdvancements #ImmunotherapySuccess #Cancer
The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%.
![](https://www.medtourcn.com/wp-content/uploads/2023/12/12210.png)
![](https://www.medtourcn.com/wp-content/uploads/2023/12/12211.jpg)